Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan
- PMID: 17656464
- DOI: 10.1210/en.2007-0155
Transforming growth factor-beta blocks inhibin binding to different target cell types in a context-dependent manner through dual mechanisms involving betaglycan
Abstract
Inhibin antagonizes activin and bone morphogenetic protein actions by sequestering their type II receptors in high-affinity complexes with betaglycan, a coreceptor that inhibin shares with TGF-beta. To clarify the nature and extent of interactions between inhibin and TGF-beta, we therefore examined 1) the mutual competition between these ligands for binding, 2) the regulation of endogenous betaglycan expression by inhibin and TGF-beta isoforms, and 3) the consequences of such betaglycan regulation for subsequent inhibin binding in mouse Leydig (TM3), Sertoli (TM4), adrenocortical cancer (AC), and gonadotroph (LbetaT2) cell lines, chosen to model cellular targets for local and endocrine actions of inhibin. Recognized inhibin, activin, and TGF-beta binding proteins and TGF-beta/activin signaling components were expressed by all four cell types, but AC and LbetaT2 cells notably lacked the type II receptor for TGF-beta, TbetaRII. Overnight treatment of TM3 and TM4 cells with TGF-beta1 suppressed the levels of betaglycan mRNA by 73 and 46% of control and subsequent [(125)I]inhibin A binding by 64 and 41% of control (IC(50) of 54 and 92 pm), respectively. TGF-beta2 acted similarly. TGF-beta pretreatments commensurately decreased the [(125)I]inhibin A affinity labeling of betaglycan on TM3 and TM4 cells. TGF-beta isoforms as direct competitors blocked up to 60% of specific inhibin A binding sites on TM3 and TM4 cells but with 9- to 17-fold lower potency than when acting indirectly via regulation of betaglycan. Only the competitive action of TGF-beta was observed with TbetaRII-deficient AC and LbetaT2 cells. Neither inhibin A nor inhibin B regulated betaglycan mRNA or competed for binding of [(125)I]TGF-beta1 or -beta2. Thus, inhibin binding to its target cell types is controlled by TGF-beta through dual mechanisms of antagonism, the operation of which vary with cell context and display different sensitivities to TGF-beta. In contrast, TGF-beta binding is relatively insensitive to the presence of either inhibin A or inhibin B.
Similar articles
-
Transforming growth factor-beta modulates inhibin A bioactivity in the LbetaT2 gonadotrope cell line by competing for binding to betaglycan.Mol Endocrinol. 2002 Dec;16(12):2754-63. doi: 10.1210/me.2002-0014. Mol Endocrinol. 2002. PMID: 12456797
-
Betaglycan binds inhibin and can mediate functional antagonism of activin signalling.Nature. 2000 Mar 23;404(6776):411-4. doi: 10.1038/35006129. Nature. 2000. PMID: 10746731
-
Properties of inhibin binding to betaglycan, InhBP/p120 and the activin type II receptors.Mol Cell Endocrinol. 2002 Oct 31;196(1-2):79-93. doi: 10.1016/s0303-7207(02)00227-7. Mol Cell Endocrinol. 2002. PMID: 12385827
-
A Tale of Two Proteins: Betaglycan, IGSF1, and the Continuing Search for the Inhibin B Receptor.Trends Endocrinol Metab. 2020 Jan;31(1):37-45. doi: 10.1016/j.tem.2019.08.014. Epub 2019 Oct 22. Trends Endocrinol Metab. 2020. PMID: 31648935 Review.
-
Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan.Mol Cell Endocrinol. 2002 Feb 25;188(1-2):254-60. doi: 10.1016/s0303-7207(02)00037-0. Mol Cell Endocrinol. 2002. PMID: 11911962 Review.
Cited by
-
Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-β signaling pathway in nasopharyngeal carcinoma.Cancer Sci. 2018 Nov;109(11):3416-3427. doi: 10.1111/cas.13780. Epub 2018 Oct 20. Cancer Sci. 2018. PMID: 30151927 Free PMC article.
-
Elevated level of inhibin-alpha subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer.Br J Cancer. 2009 Jun 2;100(11):1784-93. doi: 10.1038/sj.bjc.6605089. Epub 2009 May 12. Br J Cancer. 2009. PMID: 19436293 Free PMC article.
-
Endogenous betaglycan is essential for high-potency inhibin antagonism in gonadotropes.Mol Endocrinol. 2009 Jul;23(7):1033-42. doi: 10.1210/me.2009-0021. Epub 2009 Apr 16. Mol Endocrinol. 2009. PMID: 19372236 Free PMC article.
-
TGFBR3L is an inhibin B co-receptor that regulates female fertility.Sci Adv. 2021 Dec 17;7(51):eabl4391. doi: 10.1126/sciadv.abl4391. Epub 2021 Dec 15. Sci Adv. 2021. PMID: 34910520 Free PMC article.
-
Multiple Soluble TGF-β Receptors in Addition to Soluble Endoglin Are Elevated in Preeclamptic Serum and They Synergistically Inhibit TGF-β Signaling.J Clin Endocrinol Metab. 2017 Aug 1;102(8):3065-3074. doi: 10.1210/jc.2017-01150. J Clin Endocrinol Metab. 2017. PMID: 28633389 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources